Notice: This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GEMP vs. ALTS, ORMP, MNOV, SKYE, BHST, CUE, SLS, ANRO, IMUX, and CTORShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Janone (ALTS), Oramed Pharmaceuticals (ORMP), MediciNova (MNOV), Skye Bioscience (SKYE), BioHarvest Sciences (BHST), Cue Biopharma (CUE), SELLAS Life Sciences Group (SLS), Alto Neuroscience (ANRO), Immunic (IMUX), and Citius Oncology (CTOR). Gemphire Therapeutics vs. Janone Oramed Pharmaceuticals MediciNova Skye Bioscience BioHarvest Sciences Cue Biopharma SELLAS Life Sciences Group Alto Neuroscience Immunic Citius Oncology Janone (NASDAQ:ALTS) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has higher earnings and valuation, ALTS or GEMP? Janone has higher revenue and earnings than Gemphire Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanone$39.61M2.34-$7.81MN/AN/AGemphire TherapeuticsN/AN/A-$23.64MN/AN/A Do insiders and institutionals hold more shares of ALTS or GEMP? 6.3% of Janone shares are owned by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are owned by institutional investors. 4.9% of Janone shares are owned by company insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor ALTS or GEMP? In the previous week, Janone had 1 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 1 mentions for Janone and 0 mentions for Gemphire Therapeutics. Janone's average media sentiment score of 0.00 equaled Gemphire Therapeutics'average media sentiment score. Company Overall Sentiment Janone Neutral Gemphire Therapeutics Neutral Does the MarketBeat Community believe in ALTS or GEMP? Gemphire Therapeutics received 289 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformJanoneN/AN/AGemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% Is ALTS or GEMP more profitable? Gemphire Therapeutics' return on equity of -419.70% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets JanoneN/A -2,940.01% -39.81% Gemphire Therapeutics N/A -419.70%-173.05% Which has more volatility & risk, ALTS or GEMP? Janone has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. SummaryGemphire Therapeutics beats Janone on 5 of the 9 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.85M$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / SalesN/A311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book2.976.747.634.64Net Income-$23.64M$138.11M$3.18B$245.69M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$1.60-2.2%N/A-69.3%$23.85MN/A0.009ALTSJanoneN/A$6.90+10.6%N/AN/A$97.08M$39.61M0.00170News CoverageORMPOramed Pharmaceuticals1.4757 of 5 stars$2.40-2.0%N/A-33.0%$96.74M$1.34M21.8210Analyst DowngradeMNOVMediciNova2.4415 of 5 stars$1.97+5.3%$9.00+356.9%+35.6%$96.63M$1M-9.3810Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumeSKYESkye Bioscience1.2495 of 5 stars$3.16+3.3%$18.67+490.7%-52.1%$95.87MN/A0.0011News CoverageBHSTBioHarvest SciencesN/A$5.78+3.2%$13.00+124.9%N/A$94.94M$22.43M-4.63N/AGap UpCUECue Biopharma4.1329 of 5 stars$1.49+4.9%$5.00+235.6%-36.5%$94.39M$5.49M-1.6660SLSSELLAS Life Sciences Group0.6227 of 5 stars$1.32+3.9%N/A+48.5%$92.90M$1M-1.9110News CoverageANROAlto Neuroscience1.59 of 5 stars$3.37+3.2%$20.00+494.4%-76.2%$90.75MN/A0.00N/AIMUXImmunic2.3095 of 5 stars$1.00+4.5%$12.67+1,166.7%-1.7%$90.08MN/A-0.8170Analyst ForecastNews CoverageGap UpCTORCitius OncologyN/A$1.25-2.3%$3.00+140.0%N/A$89.44MN/A0.00N/AEarnings ReportNews Coverage Related Companies and Tools Related Companies Janone Competitors Oramed Pharmaceuticals Competitors MediciNova Competitors Skye Bioscience Competitors BioHarvest Sciences Competitors Cue Biopharma Competitors SELLAS Life Sciences Group Competitors Alto Neuroscience Competitors Immunic Competitors Citius Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GEMP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
